High Mortality Rate in Severe COVID-19 Despite Tocilizumab Administration: A Case Series
Abstract
Introduction: Tocilizumab is a potential therapeutic agent for modulating cytokine storms, a known cause of multiorgan failure and mortality in severe COVID-19. However, recent studies present conflicting results regarding its outcome and effectiveness. This study aims to assess the outcomes of severe COVID-19 patients treated with tocilizumab.
Objective: We report the mortality rate of patients with severe COVID-19 after tocilizumab administration.
Methods: A case series study involving 11 patients was conducted in the intensive care unit. Data on demographics, medical history, length of hospital stay, vital signs, laboratory and radiology examination, and drugs administered were collected. Statistical analysis used IBM SPSS version 17.
Results: The patient mortality rate reached 72.7%, with a median of two and 4.5 days of tocilizumab administration in patients who recovered and died, respectively. Comorbidities included hypertension (27.3%), type 2 diabetes mellitus (45.5%), and obesity (63.6%). Other therapies co-administered with tocilizumab include antibiotics, vasopressors, convalescent plasma, and remdesivir. Despite promising changes in laboratory parameters in almost every patient, radiological improvement was found in only 28.58% of patients.
Conclusion: This study highlights that tocilizumab administration in severe COVID-19 has a good safety profile, with no serious adverse effect observed, although a high mortality rate was observed even after tocilizumab administration in patients with severe COVID-19.
Keywords
References
Alattar, R., Ibrahim, T. B. H., Shaar, S. H., Abdalla, S., Shukri, K., Daghfal, J. N., Khatib, M. Y., Aboukamar, M., Abukhattab, M., Alsoub, H. A., Almaslamani, M. A., & Omrani, A. S. (2020). Tocilizumab for the treatment of severe coronavirus disease 2019. Journal of Medical Virology, 92(10), 2042–2049. https://doi.org/10.1002/jmv.25964
AlBahrani, S., Al-Tawfiq, J. A., Alshaer, A. R., Shilash, A., Alswefy, K., Al-Zayer, R. S., & Abouelela, A. M. (2021). A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital. Journal of Epidemiology and Global Health, 11(2), 233–237. https://doi.org/10.2991/jegh.k.210112.001
Albertini, L., Soletchnik, M., Razurel, A., Cohen, J., Bidegain, F., Fauvelle, F., Safrano, G., Piquet, J., Maurer, C., & Goldgran-Toledano, D. (2021). Observational study on off-label use of tocilizumab in patients with severe COVID-19. European Journal of Hospital Pharmacy, 28(1), 22–27. https://doi.org/10.1136/ejhpharm-2020-002414
Burhan, E., Susanto, A. D., Nasution, S. A., Ginanjar, E., Pitoyo, W., Susilo, A., Firdaus, I., Santoso, A., Arifa, D., Arif, S. K., Wulung, N. G. H. L., Adityaningsih, D., Syam, F., Rasmin, M., Rengganis, I., Sukrisman, L., Wiyono, W. H., Isbaniah, F., Elhidsi, M., … Sambo, M. (2020). Pedoman Tatalaksana COVID-19 (3rd ed.).
Campochiaro, C., Tomelleri, A., Matucci-Cerinic, M., & Dagna, L. (2022). One year later: The case of tocilizumab in COVID-19. European Journal of Internal Medicine, 95(October 2021), 5–6. https://doi.org/10.1016/j.ejim.2021.10.024
CDC COVID-19 Response Team. (2020). Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR. Morbidity and Mortality Weekly Report, 69(12), 343–346. https://doi.org/10.15585/mmwr.mm6912e2
Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. del M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M. E., Asensi, V., Horcajada, J. P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J. A., Fortun, J., … Sterne, J. A. C. (2021). Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA, 326(6), 499. https://doi.org/10.1001/jama.2021.11330
Keske, Ş., Tekin, S., Sait, B., İrkören, P., Kapmaz, M., Çimen, C., Uğur, S., Çelebi, İ., Bakır, V. O., Palaoğlu, E., Şentürk, E., Çağlayan, B., Çakar, N., Tabak, L., & Ergönül, Ö. (2020). Appropriate use of tocilizumab in COVID-19 infection. International Journal of Infectious Diseases, 99, 338–343. https://doi.org/10.1016/j.ijid.2020.07.036
McKenzie, M. G., Lee, Y. (Michelle), Mathew, J., Anderson, M., Vo, A. T., Akinyele, S., & Narayanan, M. (2022). Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series. Journal of Pharmacy Practice, 35(4), 587–592. https://doi.org/10.1177/08971900211002353
Onder, G., Rezza, G., & Brusaferro, S. (2020). Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. In JAMA - Journal of the American Medical Association. https://doi.org/10.1001/jama.2020.4683
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine, 46(6), 1294–1297. https://doi.org/10.1007/s00134-020-06028-z
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., Ballerini, P. F., Sciascia, R., Zammarchi, L., Para, O., Scotton, P. G., Inojosa, W. O., Ravagnani, V., Salerno, N. D., Sainaghi, P. P., … Costantini, M. (2021). Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine, 181(1), 24–31. https://doi.org/10.1001/JAMAINTERNMED.2020.6615
Veiga, V. C., Prats, J. A. G. G., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., MacHado, F. R., Lopes, R. D., Berwanger, O., Azevedo, L. C. P., Avezum, Á., Lisboa, T. C., Rojas, S. S. O., Coelho, J. C., Leite, R. T., Carvalho, J. C., Andrade, L. E. C., Sandes, A. F., Pintão, M. C. T., … Scheinberg, P. (2021). Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, 372. https://doi.org/10.1136/BMJ.N84
World Health Organization. (2022). Therapeutics and COVID-19: living guideline.
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., Zhang, X., Pan, A., & Wei, H. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America, 117(20), 10970–10975. https://doi.org/10.1073/pnas.2005615117
DOI: 10.24815/jks.v24i3.37069
Refbacks
- There are currently no refbacks.